Wird geladen...
Retrospective Toxicological Profiling of Radium-223 Dichloride for the Treatment of Bone Metastases in Prostate Cancer Using Adverse Event Data
Background and Objective: Radium-223 dichloride (Xofigo(®)) is a calcium mimetic agent approved for the treatment of castration-resistant prostate cancer patients with symptomatic bone metastases and no known visceral metastatic disease. This targeted, α-particle-emitting therapy has demonstrated si...
Gespeichert in:
| Veröffentlicht in: | Medicina (Kaunas) |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
MDPI
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6572036/ https://ncbi.nlm.nih.gov/pubmed/31100964 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/medicina55050149 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|